WEKO3
アイテム
{"_buckets": {"deposit": "170de003-8eac-4f68-8776-8c22dfdcee31"}, "_deposit": {"id": "12678", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "12678"}, "status": "published"}, "_oai": {"id": "oai:niigata-u.repo.nii.ac.jp:00012678", "sets": ["456", "1030"]}, "item_7_alternative_title_1": {"attribute_name": "その他のタイトル", "attribute_value_mlt": [{"subitem_alternative_title": "Multi-institutional Randomized Control Trial on the Efficacy of Adjuvant Chemotherapy Using Gemcitabine : A Preliminary Study"}]}, "item_7_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2005-02", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "2", "bibliographicPageEnd": "94", "bibliographicPageStart": "90", "bibliographicVolumeNumber": "119", "bibliographic_titles": [{"bibliographic_title": "新潟医学会雑誌"}, {"bibliographic_title": "新潟医学会雑誌", "bibliographic_titleLang": "en"}]}]}, "item_7_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Background: We evaluated gemcitabine as postoperative adjuvant chemotherapy for patients with resectable advanced pancreatic cancer. Study design: Multi-institutional randomized control trial for phase IE clinical study. Patients and Methods: Patients who underwent a curative surgery for the pancreatic cancer of Stage n, fll, and F a were enrolled in this study. The chemotherapy group has been received administration of biweekly 1000mg/m2 gemcitabine for 6 months after surgery, while the surgery-alone group has not been received any anticancer drug. The primary end-point was the disease-free survival, over-all survival and feasibility. Results: Twelve patients were enrolled in this trial from 7 institutions from November 2001 to August 2003. The chemotherapy was well tolerated with mild symptomatic and hematologic toxi-cities. The Grade 3 toxicity was observed only in two patients; one was nausea and vomiting requiring dripped infusion and the other was leucocytopenia. However, from the close micro-scopic examination, only 6 patients were eligible. Conclusions: Adjuvant systemic chemotherapy using gemcitabine was feasible with acceptable adverse effects. Further investigation for gemcitabine - based chemotherapy is warranted.", "subitem_description_type": "Abstract"}]}, "item_7_publisher_7": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "新潟医学会"}]}, "item_7_select_19": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_7_source_id_11": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AN00182415", "subitem_source_identifier_type": "NCID"}]}, "item_7_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "00290440", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "黒崎, 功"}], "nameIdentifiers": [{"nameIdentifier": "84402", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "二瓶, 幸栄"}], "nameIdentifiers": [{"nameIdentifier": "84403", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "横山, 直行"}], "nameIdentifiers": [{"nameIdentifier": "84404", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "畠山, 勝義"}], "nameIdentifiers": [{"nameIdentifier": "84405", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "土屋, 嘉昭"}], "nameIdentifiers": [{"nameIdentifier": "84406", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "清水, 武昭"}], "nameIdentifiers": [{"nameIdentifier": "84407", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2019-08-07"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "KJ00004300071.pdf", "filesize": [{"value": "604.4 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 604400.0, "url": {"label": "KJ00004300071.pdf", "url": "https://niigata-u.repo.nii.ac.jp/record/12678/files/KJ00004300071.pdf"}, "version_id": "760d2ab3-b57b-4d06-9813-42199a526520"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "膵癌", "subitem_subject_scheme": "Other"}, {"subitem_subject": "gemcitabine", "subitem_subject_scheme": "Other"}, {"subitem_subject": "無作為化比較試験", "subitem_subject_scheme": "Other"}, {"subitem_subject": "術後補助療法", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "jpn"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "膵癌切除例に対するGemcitabineを用いた多施設共同Randomized Control Trial : 中間報告とその問題点", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "膵癌切除例に対するGemcitabineを用いた多施設共同Randomized Control Trial : 中間報告とその問題点"}, {"subitem_title": "膵癌切除例に対するGemcitabineを用いた多施設共同Randomized Control Trial : 中間報告とその問題点", "subitem_title_language": "en"}]}, "item_type_id": "7", "owner": "1", "path": ["456", "1030"], "permalink_uri": "http://hdl.handle.net/10191/4513", "pubdate": {"attribute_name": "公開日", "attribute_value": "2007-05-10"}, "publish_date": "2007-05-10", "publish_status": "0", "recid": "12678", "relation": {}, "relation_version_is_last": true, "title": ["膵癌切除例に対するGemcitabineを用いた多施設共同Randomized Control Trial : 中間報告とその問題点"], "weko_shared_id": null}
膵癌切除例に対するGemcitabineを用いた多施設共同Randomized Control Trial : 中間報告とその問題点
http://hdl.handle.net/10191/4513
http://hdl.handle.net/10191/45138bc1b44e-db85-44e6-b003-d2ccc43cd100
名前 / ファイル | ライセンス | アクション |
---|---|---|
KJ00004300071.pdf (604.4 kB)
|
|
Item type | 紀要論文 / Departmental Bulletin Paper(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2007-05-10 | |||||
タイトル | ||||||
タイトル | 膵癌切除例に対するGemcitabineを用いた多施設共同Randomized Control Trial : 中間報告とその問題点 | |||||
タイトル | ||||||
言語 | en | |||||
タイトル | 膵癌切除例に対するGemcitabineを用いた多施設共同Randomized Control Trial : 中間報告とその問題点 | |||||
言語 | ||||||
言語 | jpn | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | 膵癌 | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | gemcitabine | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | 無作為化比較試験 | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | 術後補助療法 | |||||
資源タイプ | ||||||
資源 | http://purl.org/coar/resource_type/c_6501 | |||||
タイプ | departmental bulletin paper | |||||
その他のタイトル | ||||||
その他のタイトル | Multi-institutional Randomized Control Trial on the Efficacy of Adjuvant Chemotherapy Using Gemcitabine : A Preliminary Study | |||||
著者 |
黒崎, 功
× 黒崎, 功× 二瓶, 幸栄× 横山, 直行× 畠山, 勝義× 土屋, 嘉昭× 清水, 武昭 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Background: We evaluated gemcitabine as postoperative adjuvant chemotherapy for patients with resectable advanced pancreatic cancer. Study design: Multi-institutional randomized control trial for phase IE clinical study. Patients and Methods: Patients who underwent a curative surgery for the pancreatic cancer of Stage n, fll, and F a were enrolled in this study. The chemotherapy group has been received administration of biweekly 1000mg/m2 gemcitabine for 6 months after surgery, while the surgery-alone group has not been received any anticancer drug. The primary end-point was the disease-free survival, over-all survival and feasibility. Results: Twelve patients were enrolled in this trial from 7 institutions from November 2001 to August 2003. The chemotherapy was well tolerated with mild symptomatic and hematologic toxi-cities. The Grade 3 toxicity was observed only in two patients; one was nausea and vomiting requiring dripped infusion and the other was leucocytopenia. However, from the close micro-scopic examination, only 6 patients were eligible. Conclusions: Adjuvant systemic chemotherapy using gemcitabine was feasible with acceptable adverse effects. Further investigation for gemcitabine - based chemotherapy is warranted. | |||||
書誌情報 |
新潟医学会雑誌 en : 新潟医学会雑誌 巻 119, 号 2, p. 90-94, 発行日 2005-02 |
|||||
出版者 | ||||||
出版者 | 新潟医学会 | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 00290440 | |||||
書誌レコードID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AN00182415 | |||||
著者版フラグ | ||||||
値 | publisher |